KALC-IC 2024

Session VII (C).
Satellite Symposium I (A).		Room A (Crystal Ballroom 3)
Date & Time	November 7(Thu), 08:30-09:10
Chair(s)	Min Ki Lee (Pusan National Univ., Korea)
Speaker	08:30-09:10 Real world treatment experience with Tepotinib in patients with METex14 skipping mutation NSCLC in Korea Beung Chul Ahn (National Cancer Center, Korea)

Session VII (C).
Session I (A). New generation of immunotherapy		Room A (Crystal Ballroom 3)
Date & Time	November 7(Thu), 09:20-10:20
Chair(s)	Kye Young Lee (Konkuk Univ., Korea), Derek Huang (National Taiwan Univ., Taiwan)
Speaker	09:20-09:40 Current standard of care with immunotherapy and clinical unmet needs Jii Bum Lee (Yonsei Univ., Korea) 09:40-10:00 Update of CAR-T therapy in solid tumors Hyungseok Seo (College of Pharmacy, Seoul National Univ., Korea) 10:00-10:20 Update of BiTE therapy in lung cancer Derek Huang (National Taiwan Univ., Taiwan)

Session VII (C).
Session II (A). ADCs in thoracic oncology		Room A (Crystal Ballroom 3)
Date & Time	November 7(Thu), 10:35-11:35
Chair(s)	Chan Kwon Park (The Catholic Univ. of Korea, Korea), Lizza E.L. Hendriks (Maastricht University Medical Center, Netherlands)
Speaker	10:35-10:50 Current development of ADCs in thoracic oncology Benjamin Besse (Paris-Saclay Univ., France) 10:50-11:05 Toxicities of ADCs Yasushi Goto (National Cancer Center Hospital, Japan) 11:05-11:20 Predictive biomarkers of ADCs Lizza E.L. Hendriks (Maastricht University Medical Center, Netherlands) 11:20-11:35 Novel antibody-drug conjugates and new approaches Dae Ho Lee (Univ. of Ulsan, Korea)

Session VII (C).
Plenary Session I.		Room A+B+C (Crystal Ballroom 1+2+3)
Date & Time	November 7(Thu), 11:50-12:30
Chair(s)	Jae Cheol Lee (Univ. of Ulsan, Korea)
Speaker	11:50-12:30 Biomarker driven personalized treatment of lung cancer : Best drugs first? Benjamin Besse (Paris-Saclay Univ., France)

Session VII (C).
Luncheon Symposium I.		Room A+B+C (Crystal Ballroom 1+2+3)
Date & Time	November 7(Thu), 12:30-13:10
Chair(s)	Dong-Wan Kim (Seoul National Univ., Korea)
Speaker	12:30-13:10 Paradigm shift for resectable NSCLC : Pembrolizumab perioperative treatment Bin-Chi Liao (National Taiwan University Cancer Center, Taiwan)

Session VII (C).
Session III (A). Update of thymic tumors		Room A (Crystal Ballroom 3)
Date & Time	November 7(Thu), 13:30-14:30
Chair(s)	Suk Ki Cho (Seoul National Univ., Korea), Malgorzata Szolkowska (Institute of Tuberculosis and Lung Diseases, Poland)
Speaker	13:30-13:50 Diagnosis thymic tumors Malgorzata Szolkowska (Institute of Tuberculosis and Lung Diseases, Poland) 13:50-14:10 Debate on complete resection in thymic tumors Kook Nam Han (Chung-Ang Univ., Korea) 14:10-14:30 New systemic treatment in thymic tumors Yaewon Yang (Chungbuk National Univ., Korea)

Session VII (C).
Session IV (A). Update of EGFR-mutant NSCLC		Room A (Crystal Ballroom 3)
Date & Time	November 7(Thu), 14:45-15:45
Chair(s)	Cheol Hyeon Kim (Korea Cancer Center Hospital, Korea), James Chih-Hsin Yang (National Taiwan Univ., Taiwan)
Speaker	14:45-15:05 Optimising first-line treatment in EGFR-mutant advanced NSCLC Hidehito Horinouchi (National Cancer Center, Japan) 15:05-15:25 Acquired resistance mechanism in patients treated with third-generation EGFR TKIs James Chih-Hsin Yang (National Taiwan Univ., Taiwan) 15:25-15:45 Role of ADCs in patients treated with third-generation EGFR TKIs Yun-Gyoo Lee (Sungkyunkwan Univ., Korea)

Session VII (C).
Satellite Symposium II (A).		Room A (Crystal Ballroom 3)
Date & Time	November 7(Thu), 16:00-16:40
Chair(s)	Sei-Hoon Yang (Wonkwang Univ., Korea)
Speaker	16:00-16:40 How to improve the chance of cure for EGFRm+ NSCLC with Osimertinib Min Hee Hong (Yonsei Univ., Korea)

Session VII (C).
Session I (B). Interventional pulmonology in thoracic malignancy		Room B (Crystal Ballroom 2)
Date & Time	November 7(Thu), 09:20-10:20
Chair(s)	Young Sik Park (Seoul National Univ., Korea), Neal Navani (University College London Hospital, UK)
Speaker	09:20-09:40 Advances in bronchoscopic techniques for diagnosing peripheral lung cancer Noriaki Kurimoto (Shimane Univ., Japan) 09:40-10:00 Updates on EBUS for nodal staging and tissue acquisition Neal Navani (University College London Hospital, UK) 10:00-10:20 Optimal management of recurrent malignant pleural effusions Pyng Lee (National University Hospital, Singapore)

Session VII (C).
Session II (B). Treatment of lung cancer in patients with severe respiratory diseases		Room B (Crystal Ballroom 2)
Date & Time	November 7(Thu), 10:35-11:35
Chair(s)	Hoseok I (Pusan National Univ., Korea), Jeong Eun Lee (Chungnam National Univ., Korea)
Speaker	10:35-10:55 Treatment and prognosis of lung cancer in patients with severe chronic obstructive pulmonary disease(COPD) Sei Won Lee (Univ. of Ulsan, Korea) 10:55-11:15 Postoperative acute lung injury Kyeongman Jeon (Sungkyunkwan Univ., Korea) 11:15-11:35 Pneumonic infiltration in patients treated with immuno-oncology agents: Causes and impact on lung cancer prognosis Cheol Kyu Park (Chonnam National Univ., Korea)

Session VII (C).
Session III (B). Management of ultra-central lung tumor		Room B (Crystal Ballroom 2)
Date & Time	November 7(Thu), 13:30-14:30
Chair(s)	Jin Hee Kim (Keimyung Univ., Korea), Yeonsil Kim (The Catholic Univ. of Korea, Korea)
Speaker	13:30-13:50 Salvage surgery after definitive chemoradiotherapy for lung cancer Jae Hyun Jeon (Seoul National Univ., Korea) 13:50-14:10 SBRT to ultra-central lung cancer Sung Ho Moon (National Cancer Center, Korea) 14:10-14:30 Conventional radiotherapy for isolated lymph node metastasis after surgery or radiotherapy for lung cancer Katsuyuki Shirai (Jichi Medical University Hospital, Japan)

Session VII (C).
Session IV (B). Optimal treatment approaches and sequential strategies for brain metastases from NSCLC		Room B (Crystal Ballroom 2)
Date & Time	November 7(Thu), 14:45-15:45
Chair(s)	Hong-Gyun Wu (Seoul National Univ., Korea), Si Yeol Song (Univ. of Ulsan, Korea)
Speaker	14:45-15:00 Case presentation for brain metastases from NSCLC Byoung Hyuck Kim (Seoul National Univ., Korea) 15:00-15:15 Systemic therapy for brain metastases from NSCLC Beung Chul Ahn (National Cancer Center, Korea) 15:15-15:30 Stereotactic Radiosurgery for brain metastases from NSCLC Eun Jung Lee (Seoul National Univ., Korea) 15:30-15:45 Whole-brain radiation therapy for brain metastases from NSCLC Jaeho Cho (Yonsei Univ., Korea)

Session VII (C).
Satellite Symposium II (B).		Room B (Crystal Ballroom 2)
Date & Time	November 7(Thu), 16:00-16:40
Chair(s)	Ki Hyeong Lee (Chungbuk National Univ., Korea)
Speaker	16:00-16:40 Translating clinical trial results into real-world impact: Brigatinib case studies Jii Bum Lee (Yonsei Univ., Korea)

Session VII (C).
Session I (C). Low-dose computed tomography lung cancer screening: An update		Room C (Crystal Ballroom 1)
Date & Time	November 7(Thu), 09:20-10:20
Chair(s)	Tae Jung Kim (Sungkyunkwan Univ., Korea), Eunji Choi (Weill Cornell Medicine, Cornell Univ., USA)
Speaker	09:20-09:35 Low-dose computed tomography lung cancer screening: Real-world evidence David Baldwin (Universiy of Nottingham, UK) 09:35-09:50 Risk-based lung cancer screening and racial disparities in the U.S. Eunji Choi (Weill Cornell Medicine, Cornell Univ., USA) 09:50-10:05 Low-dose computed tomography lung cancer screening: Family history of lung cancer Yeun-Chung Chang (National Taiwan Univ., Taiwan) 10:05-10:20 Low-dose computed tomography lung cancer screening: AI-based risk stratification Hyungjin Kim (Seoul National Univ., Korea)

Session VII (C).
Session II (C). Joint Symposium with HIRA (KOR)		Room C (Crystal Ballroom 1)
Date & Time	November 7(Thu), 10:35-11:35
Chair(s)	Sung Yong Lee (Korea Univ., Korea), Hye Ryun Kim (Yonsei Univ., Korea)
Speaker	10:35-10:55 Economic evaluation of new lung cancer treatments Kookhee Kim (Health Insurance Review and Assessment Service (HIRA), Korea) 10:55-11:10 Reimbursement issues in the treatment of NSCLC with rare oncogenic alterations Shinkyo Yoon (Univ. of Ulsan, Korea) 11:10-11:25 The current reimbursement status of anti cancer agents in lung cancer patients; focusing the cases with gray zone Min Hee Hong (Yonsei Univ., Korea) 11:25-11:35 Panel discussion Kookhee Kim (Health Insurance Review and Assessment Service (HIRA), Korea), Shinkyo Yoon (Univ. of Ulsan, Korea), Min Hee Hong (Yonsei Univ., Korea)

Session VII (C).
Session III (C). Optimal treatment for elderly patients		Room C (Crystal Ballroom 1)
Date & Time	November 7(Thu), 13:30-14:30
Chair(s)	Deog Gon Cho (The Catholic Univ. of Korea, Korea), Chanyoot Bandidwattanawong (Navamindradhiraj Univ., Thailand)
Speaker	13:30-13:50 Surgical treatment in elderly patients: Balancing risks and benefits Junghee Lee (Sungkyunkwan Univ., Korea) 13:50-14:10 Systemic treatment in elderly patients Jin-Soo Kim (Seoul National Univ., Korea) 14:10-14:30 How to select the most proper treatment for the elderly lung cancer patients? Chanyoot Bandidwattanawong (Navamindradhiraj Univ., Thailand)

Session VII (C).
Session IV (C). Oral Presentation I		Room C (Crystal Ballroom 1)
Date & Time	November 7(Thu), 14:45-15:45
Chair(s)	Yoo Duk Choi (Chonnam National Univ., Korea), Sunhee Chang (Inje Univ., Korea)
Speaker	14:45-14:55 Spatial transcriptomics reveals spatially diverse cancer-associated fibroblasts in lung squamous cell carcinoma linked to tumor progression Kwon Joong Na (Seoul National Univ., Korea) 14:55-15:05 Single-cell RNA sequencing revealed that changes in monocytes are involved in the prognosis of durvalumab consolidation therapy following chemoradiotherapy Duk-Ki Kim (Chungnam National Univ., Korea) 15:05-15:15 Landscape of tumor heterogeneity and tumor mutational burden (TMB) in non-small cell lung cancer (NSCLC) Jong-Yeob Kim (Feinberg School of Medicine, Northwestern Univ., USA) 15:15-15:25 Induction of malignant transformation in human bronchial epithelial cells and lung organoids by chronic exposure to whole cigarette smoke extract Joo-Eun Lee (Chungnam National Univ., Korea) 15:25-15:35 Identification of GREM-1 and GAS6 as specific biomarkers for cancer-associated fibroblasts derived from patients with non-small cell lung cancer Bo-Guen Kim (Sungkyunkwan Univ., Korea) 15:35-15:45 Spatially defined co-culture model of non-small cell lung cancer organoids and cancer-associated fibroblasts to investigate phenotypic heterogeneity Cheol Kyu Park (Chonnam National Univ., Korea)

Session VII (C).
Satellite Symposium III (A).		Room A (Crystal Ballroom 3)
Date & Time	November 8(Fri), 08:20-09:00
Chair(s)	Seung Hun Jang (Hallym Univ., Korea)
Speaker	08:20-09:00 Evolving paradigm of ALK+ mNSCLC patient treatment with Lorlatinib CROWN 5-year data Beung Chul Ahn (National Cancer Center, Korea)

Session VII (C).
Session V (A). Small Cell Lung Cancer Recent Update		Room A (Crystal Ballroom 3)
Date & Time	November 8(Fri), 09:10-10:10
Chair(s)	Tae Min Kim (Seoul National Univ., Korea), Takafumi Koyama (National Cancer Center, Japan)
Speaker	09:10-09:25 Molecular biology and subtypes of SCLC Sehhoon Park (Sungkyunkwan Univ., Korea) 09:25-09:40 Update of radiation in SCLC Young Seob Shin (Univ. of Ulsan, Korea) 09:40-09:55 Recent update of systemic treatment in SCLC: immunotherapy Eun Joo Kang (Korea Univ., Korea) 09:55-10:10 Current status and future challenges of antibody-drug conjugates in precision oncology of SCLC Takafumi Koyama (National Cancer Center, Japan)

Session VII (C).
Session VI (A). Immunotherapy in early-stage NSCLC		Room A (Crystal Ballroom 3)
Date & Time	November 8(Fri), 10:25-11:25
Chair(s)	In Jae Oh (Chonnam National Univ., Korea), Stephanie Saw Pei (National Cancer Centre Singapore, Singapore)
Speaker	10:25-10:40 Treatment Strategies combining IO in high PD-L1 early-stage NSCLC Stephanie Saw Pei (National Cancer Centre Singapore, Singapore) 10:40-10:55 Treatment Strategies combining IO in low PD-L1 early-stage NSCLC Sun Min Lim (Yonsei Univ., Korea) 10:55-11:10 Response assessment in preoperative immunotherapy Jooae Choe (Univ. of Ulsan, Korea) 11:10-11:25 Predictive biomarker of perioperative IO treatment Yoon La Choi (Sungkyunkwan Univ., Korea)

Session VII (C).
Luncheon Symposium II. EGFR mutant positive NSCLC(Lazertinib)		Room A+B+C (Crystal Ballroom 1+2+3)
Date & Time	November 8(Fri), 11:40-12:20
Chair(s)	Young-Chul Kim (Chonnam National Univ., Korea)
Speaker	11:40-12:20 EGFR mutation positive non-small cell lung cancer Bhumsuk Keam (Seoul National Univ., Korea)

Session VII (C).
Plenary Session II.		Room A+B+C (Crystal Ballroom 1+2+3)
Date & Time	November 8(Fri), 12:50-13:30
Chair(s)	Myung-Ju Ahn (Sungkyunkwan Univ., Korea)
Speaker	12:50-13:30 Future prospects of I-O in lung cancer management Tony Shu Kam Mok (Chinese University of Hong Kong, Hong Kong SAR, China)

Session VII (C).
Session VII (A). Treatment of NSCLC with rare mutations		Room A (Crystal Ballroom 3)
Date & Time	November 8(Fri), 13:50-14:50
Chair(s)	Jeong-Seon Ryu (Inha Univ., Korea), Sai-Hong Ignatius Ou (University of California Irvine School of Medicine, USA)
Speaker	13:50-14:05 Recent advances in HER2-mutant metastatic NSCLC Chao-Hua Chiu (Taipei Medical Univ., Taiwan) 14:05-14:20 Advances in RET fusion-positive lung cancer Jessica Lin (Massachusetts General Hospital, USA) 14:20-14:35 MET alterations in NSCLC; mutation, amplification, and overexpression Ji-Youn Han (National Cancer Center, Korea) 14:35-14:50 KRAS Sai-Hong Ignatius Ou (University of California Irvine School of Medicine, USA)

Session VII (C).
Session VIII (A). Incorporating ctDNA assays in clinical practice		Room A (Crystal Ballroom 3)
Date & Time	November 8(Fri), 15:05-16:05
Chair(s)	Taewon Jang (Kosin Univ., Korea), Aadel A. Chaudhuri (Mayo Clinic, USA)
Speaker	15:05-15:20 Role of liquid biopsy in advanced NSCLC Aaron C. Tan (The National Cancer Centre Singapore(NCCS), Singapore) 15:20-15:35 Minimal residual disease: Concept, data in NSCLC Beung Chul Ahn (National Cancer Center, Korea) 15:35-15:50 Role of liquid biopsy in monitoring adjuvant treatment: Pros Hirotsugu Kenmotsu (Shizuoka Cancer Center, Japan) 15:50-16:05 Advances in cell-free DNA liquid biopsy for lung cancer detection and management Aadel A. Chaudhuri (Mayo Clinic, USA)

Session VII (C).
Satellite Symposium III (B).		Room B (Crystal Ballroom 2)
Date & Time	November 8(Fri), 08:20-09:00
Chair(s)	Jin Hyoung Kang (The Catholic Univ. of Korea, Korea)
Speaker	08:20-09:00 A new chapter in adjuvant therapy: Alectinib for resected ALK-positive NSCLC Gyeong-Won Lee (Gyeongsang National Univ., Korea)

Session VII (C).
Session V (B). Updates on lung cancer pathology		Room B (Crystal Ballroom 2)
Date & Time	November 8(Fri), 09:10-10:10
Chair(s)	Wan-Seop Kim (Konkuk Univ., Korea), Jennifer M. Boland (Mayo Clinic, USA)
Speaker	09:10-09:30 A WHO reporting system for lung cytopathology: Standardization and clinical application Hee Jeong Cha (Univ. of Ulsan, Korea) 09:30-09:50 Pathology of invasive mucinous adenocarcinoma of the lung Yoon jin Cha (Yonsei Univ., Korea) 09:50-10:10 Diagnostic pitfalls on frozen section evaluation of low grade pulmonary neoplasms Jennifer M. Boland (Mayo Clinic, USA)

Session VII (C).
Session VI (B). Updates on emerging biomarkers and technologies for lung cancer		Room B (Crystal Ballroom 2)
Date & Time	November 8(Fri), 10:25-11:25
Chair(s)	Seung Yeon Ha (Gachon Univ., Korea), Mee Sook Roh (Dong-A Univ., Korea)
Speaker	10:25-10:45 Lung cancer screening using plasma NGS Eunhae Cho (GC Genome, Korea) 10:45-11:05 Real-world implementation of digital pathology Junya Fukuoka (Nagasaki University Graduate School of Biomedical Sciences, Japan) 11:05-11:25 Sequencing-based classification of Intrapulmonary metastasis and multiple primary lung cancer Hyo Sup Shim (Yonsei Univ., Korea)

Session VII (C).
Session VII (B). Lung cancer surgery after neoadjuvant immunotherapy		Room B (Crystal Ballroom 2)
Date & Time	November 8(Fri), 13:50-14:50
Chair(s)	In Kyu Park (Seoul National Univ., Korea), Tetsuya Mitsudomi (Kindai Univ., Japan)
Speaker	13:50-14:10 Real-world results of lung cancer surgery after neoadjuvant immunotherapy Hong Kwan Kim (Sungkyunkwan Univ., Korea) 14:10-14:30 Defining resectability after neoadjuvant immunotherapy Tetsuya Mitsudomi (Kindai Univ., Japan) 14:30-14:50 Perioperative immune-related adverse events after neoadjuvant immunotherapy Jang Ho Cho (The Catholic Univ. of Korea, Korea)

Session VII (C).
Session VIII (B). Surgical options for advanced lung cancer		Room B (Crystal Ballroom 2)
Date & Time	November 8(Fri), 15:05-16:05
Chair(s)	Yong Soo Choi (Sungkyunkwan Univ., Korea), Young Kwang Chae (Northwestern Univ., USA)
Speaker	15:05-15:25 Double lung transplantation in patients with advanced bilateral lung-limited non-small cell lung carcinoma Young Kwang Chae (Northwestern Univ., USA) 15:25-15:45 Curative salvage surgery after definite CCRT Yoichi Ohtaki (Gunma Univ., Japan) 15:45-16:05 Surgery for stage IV non-small cell lung cancer Jae Kwang Yun (Univ. of Ulsan, Korea)

Session VII (C).
Satellite Symposium III (C).		Room C (Crystal Ballroom 1)
Date & Time	November 8(Fri), 08:20-09:00
Chair(s)	Sang-We Kim (Univ. of Ulsan, Korea)
Speaker	08:20-09:00 Lurbinectedin in SCLC: Learning from clinical experiences Sun Min Lim (Yonsei Univ., Korea)

Session VII (C).
Session V (C). Oral Presentation II		Room C (Crystal Ballroom 1)
Date & Time	November 8(Fri), 09:10-10:10
Chair(s)	Yoo-Kang Kwak (The Catholic Univ. of Korea, Korea), Samina Park (Seoul National Univ., Korea)
Speaker	09:10-09:20 Perioperative outcomes of neoadjuvant chemoimmunotherapy followed by surgery in stage II-III NSCLC: A real-world study Junghee Lee (Sungkyunkwan Univ., Korea) 09:20-09:30 Preliminary analysis of lazertinib consolidation therapy in patients with locally advanced, unresectable, EGFR mutated NSCLC following chemoradiation therapy: PLATINUM trial Sung Yong Lee (Korea Univ., Korea) 09:30-09:40 What is the optimal dose and fractionation schedule for inoperable node-negative large (>5 cm) non-small cell lung cancer? Ye-Jin Yoo (Univ. of Ulsan, Korea) 09:40-09:50 Double lung transplantation in patients with metastatic lung-limited non-small cell lung carcinoma (NSCLC): A case series Young Kwang Chae (Northwestern Univ., USA) 09:50-10:00 Normal brain-sparing radiotherapy versus whole brain radiotherapy for multiple brain metastasis from non-small cell lung cancer Sangjoon Park (Yonsei Univ., Korea) 10:00-10:10 Refining patient selection for prophylactic cranial irradiation in limited-stage small-cell lung cancer: Insights from a Korean multi-institutional cohort study Hye-In Lee (Univ. of Ulsan, Korea)

Session VII (C).
Session VI (C). Oral Presentation III		Room C (Crystal Ballroom 1)
Date & Time	November 8(Fri), 10:25-11:25
Chair(s)	Jeong Eun Lee (Chungnam National Univ., Korea), Shinkyo Yoon (Univ. of Ulsan, Korea)
Speaker	10:25-10:35 Real-world insights: Treatment patterns and overall survival in patients with small-cell lung cancer in South Korea a single center experience Sehhoon Park (Sungkyunkwan Univ., Korea) 10:35-10:45 AI-powered pathologic response evaluation of post-neoadjuvant chemoimmunotherapy in NSCLC patients Kwon Joong Na (Seoul National Univ., Korea) 10:45-10:55 Enhanced thrombopoiesis supplies PD-L1 to circulating immune cells via the generation of PD-L1-Expressing platelets in lung cancer patients JaeHo Cho (Chonnam National University Medical School, Korea) 10:55-11:05 Chemotherapy plus immune checkpoint inhibitors in non-small cell lung cancer with actionable gene alterations other than EGFR, ALK, and ROS1 Ji-Eun Shin (The Catholic Univ. of Korea St. Vincent's Hospital, Korea) 11:05-11:15 Sequential hypofractionated radiotherapy followed by anti-PD-L1 atezolizumab for recurrent or refractory small cell lung cancer Yang-Gun Suh (National Cancer Center, Korea) 11:15-11:25 Imaging trajectory of transformation into small-cell carcinomas from lung adenocarcinomas undergoing TKI treatment: radiomic prediction Jihwan Choi (Sungkyunkwan Univ., Korea)

Session VII (C).
Session VII (C). 5 year Anniversary Symposium – National Lung Cancer Screening Program Part 1 (ENG)		Room C (Crystal Ballroom 1)
Date & Time	November 8(Fri), 13:50-14:50
Chair(s)	Sook-Whan Sung (Ewha Womans Univ., Korea), Jin Soo Lee (Health Insurance Review and Assessment Service (HIRA), Korea)
Speaker	13:50-14:05 Evidence of lung cancer screening and guidelines Seung Hun Jang (Hallym Univ., Korea) 14:05-14:20 History and achievement of world first national lung cancer screening program in Korea Yeol Kim (National Cancer Center, Korea) 14:20-14:35 A.I. based quality control system for national lung cancer screening program Gong Yong Jin (Jeonbuk National Univ., Korea) 14:35-14:50 Evidence for implementation of population based-lung cancer screening in Germany Jens Vogel-Claussen (Hannover Univ., Germany)

Session VII (C).
Session VII (C). 5 year Anniversary Symposium – National Lung Cancer Screening Program Part 2 (ENG)		Room C (Crystal Ballroom 1)
Date & Time	November 8(Fri), 15:05-16:05
Chair(s)	Myung-Ju Ahn (Sungkyunkwan Univ., Korea), Choon-Taek Lee (Seoul National Univ., Korea)
Speaker	15:05-15:20 Participant care and smoking cessation after lung cancer screening Seung Won Ra (Univ. of Ulsan, Korea) 15:20-15:35 Biomarker research for enhancing effectiveness of lung cancer screening Hilary Robbins (International Agency for Research on Cancer, IARC) 15:35-15:50 Expansion of target population and overdiagnosis in lung cancer screening Jin Mo Goo (Seoul National Univ., Korea) 15:50-16:05 Panel discussion Tong Ryoung Jung (Ministry of Health and Welfare, Korea), Young-Chul Kim (Chonnam National Univ., Korea), Cheolmin Lee (Seoul National Univ., Korea)

Abstract No.	Presentation Time	Abstract Title	Presenter Name	Affiliation	Country
A-0226	09:10-09:20	Perioperative outcomes of neoadjuvant chemoimmunotherapy followed by surgery in stage II-III NSCLC: A real-world study	Junghee Lee	Samsung Medical Center	Korea
A-0214	09:20-09:30	Preliminary analysis of lazertinib consolidation therapy in patients with locally advanced, unresectable, EGFR mutated NSCLC following chemoradiation therapy: PLATINUM trial	Sung Yong Lee	Korea University	Korea
A-0204	09:30-09:40	What Is the Optimal Dose and Fractionation Schedule for Inoperable Node-Negative Large (>5 cm) Non-Small Cell Lung Cancer?	Ye Jin Yoo	Asan Medical Center	Korea
A-0108	09:40-09:50	Double lung transplantation in patients with metastatic lung-limited non-small cell lung carcinoma (NSCLC): A case series	Young Chae	Northwestern University Feinberg School of Medicine	USA
A-0069	09:50-10:00	Normal brain-sparing radiotherapy versus whole brain radiotherapy for multiple brain metastasis from non-small cell lung cancer	Sangjoon Park	Severance Hospital	Korea
A-0046	10:00-10:10	Refining patient selection for prophylactic cranial irradiation in limited-stage small-cell lung cancer: Insights from a Korean multi-institutional cohort study	Hye In Lee	Asan Medical Center	Korea

Abstract No.	Poster No.	Abstract Title	Presenter Name	Affiliation	Country
A-0215	PE1-01	Engineering precision medicine for lung cancer: Antibody-mimetic scaffolds targeting EGFR	Tushar Kushwaha	All Institute of Medical Sciences	India
A-0128	PE1-02	TP53 mutations in Belarusian patients with non-small cell lung cancer	Hanna Shchayuk	Institute of Genetics and Cytology, National Academy of Sciences of Belarus	Belarus
A-0109	PE1-03	Optimized exosomal miRNA panels for early detection of non-small cell lung cancer	Da Hyun Kang	Chungnam National University	Korea
A-0060	PE1-04	Anticancer effect of Columbianadin against benzopyreneinduced lung cancer in rats: Role of PI3K/Akt/FoxO1 and inflammatory pathway	Vikas Kumar	Sam Higginbottom University of Agriculture, Technology & Sciences	India
A-0047	PE1-05	Role of exosomal proteins in brain-specific metastasis of lung cancer	Dong Ha Kim	Asan Medical Center	Korea
A-0238	PE1-06	The influence of knowledge and attitudes on smoking decisions: Case study of the Pandeyan Boyolai village community, Central Java.	Rinita Istiqomah	Yogyakarta State University	Indonesia
A-0237	PE1-07	Driver genes expression and fusions in patients with lung cancer	Yuliya Stankevich	Institute of Genetics and Cytology of the National Academy of Sciences of Belarus	Belarus
A-0233	PE1-08	Association between long non-coding RNA HOTAIR polymorphism and lung cancer risk: A meta-analysis	Farhana Sultana Mitu	Islamic University	Bangladesh
A-0232	PE1-09	A meta-analytic approach to find the association between polymorphism with in MicroRNAs and lung cancer risk	Md Abdullah Al Maruf	Islamic University	Bangladesh
A-0228	PE1-10	CTSC regulates cell growth in small cell lung cancer via YAP/PAR2 signaling pathway	Nayoung Kim	Chungnam National University Hospital	Korea
A-0208	PE1-11	Lung Organoid to understand mechanism of therapeutic resistance in lung cancer	Jinwook Choi	School of Life Sciences, Gwangju Institute of Science and Technology (gist)	Korea
A-0185	PE1-13	The impact of Living-Donor Lobar Lung Transplantation (LDLLT) procedure on the sexual function of donors and recipients: A systematic review	Rosinta Hotmaida P Purba	The Pranala Institute	Indonesia
A-0179	PE1-14	Loss of Cereblon (CRBN) enhances lung cancer cell migration and invasion through regulation of cystathionine -synthase (CBS)	Kihun Kim	Gwangju Institute of Science and Technology	Korea
A-0173	PE1-15	Parallel Accumulation-Serial Fragmentation for in-depth proteomic analysis of bronchoalveolar lavage fluid of non-small cell lung cancer	Seung Hyeun Lee	Kyung Hee University Medical Center	Korea
A-0164	PE1-16	Butanolic fraction of Asparagus racemosus root alters the JAK/STAT3 Signaling Pathway to mitigate metastasis, apoptosis, and proliferation in lung cancer	Niti Singh	Marlabs Innovation Pvt Ltd.	India
A-0161	PE1-17	Utilizing machine learning methodologies to forecast the occurence of lung cancer in patients of central region.	Manvendra Singh	Hmfa Miet	India
A-0160	PE1-18	Solid Lipid Nanoparticle of Ganodric acid in the treatment against benzopyreneinduced lung cancer in rats: Nrf2/HO-1 signaling pathway	V Kumar	Shalom Institute of Health & Allied Sciences	India
A-0156	PE1-19	Solid lipid nanoparticles of gallic acid enhances apoptosis and proliferation in rats to lessen lung cancer induced by diethylnitrosamine/2-acetylaminofluorene.	Deepika Singh	Shuats	India
A-0154	PE1-20	The incidence of hematologic paraneoplastic syndromes in newly diagnosed lung cancer patients	Roland Helmizar	Baiturrahmah University	Indonesia
A-0114	PE1-22	A pilot study to discover potential early NSCLC biomarkers in the Filipino secretome	Josemaria Alejandro Corpuz	University of the Philippines-Diliman	Philippines
A-0090	PE1-23	Recapitulation tumor microenvionments with lung cancer organoids for drug screening study	Insu Lee	Seoul National University Bundang Hospital	Korea
A-0088	PE1-24	What is our role to reduce lung cancer mortality rates?: Case studies of 7 countries with the highest lung cancer	Nadia Fazira	Andalas University	Indonesia
A-0087	PE1-25	ARAF p.S214C Mutation Enhances Sorafenib Response in Lung Cancer	Carol Lee	The Chinese University of Hong Kong	Hong Kong
A-0076	PE1-27	Enhancing tumoroid applications with regenix in advanced 3D cell culture models	Da Hye Song	Cellartgen	Korea
A-0068	PE1-28	Regenix in lung cancer PDX models: Advancing research and therapeutic potential	Da Hye Song	Cellartgen	Korea
A-0063	PE1-29	Synergistic anticancer effects of Niclosamide and Osimertinib: Repurposing drugs in autophagy for the treatment of EGFR-mutant lung cancer cells	Yuan-Ming Tsai	Tri-Service General Hospital, National Defense Medical Center	Taiwan
A-0051	PE1-30	Identification of Guanine-quadruplex forming DNA aptamer: A promising therapeutic strategy for EGFR overexpressed non-small cell lung cancer	Deepa Singh	All Institute of Medical Sciences	India
A-0050	PE1-31	Austrian biobanking and biomolecular resources research infrastructure - Important partner for research on biological samples	Luka Brcic	Medical University of Graz	Austria
A-0049	PE1-32	Clinical and genomic features of different KRAS Subtypes in non-small cell lung cancer	Soo Han Kim	Pusan National University Hospital	Korea

Abstract No.	Poster No.	Abstract Title	Presenter Name	Affiliation	Country
A-0151	PE1-34	Network pharmacology study revealed the multitargets anticancer mechanism of sesamin in NSCLC	Reny Rosalina	University of Palangka Raya	Indonesia
A-0250	PE1-35	Utilizing machine learning algorithms for enhanced lung cancer diagnosis through imaging biomarkers	Divo Helmizar	Stan Jakarta	Indonesia
A-0239	PE1-36	Deep-learning model for personalized recurrence prediction in early-stage non-small cell lung cancer	Daehwan Lee	Spidercore Inc.	Korea
A-0093	PE1-38	Increased risk of lung cancer in individuals with nontuberculous mycobacterial pulmonary disease: A Korean population-based study	Dongwon Park	Hanyang University Medical Center	Korea
A-0086	PE1-39	Deep-learning-driven prediction of lung cancer recurrence using integrated immune profiling and radiomic features from computed tomography scans	Rifaldy Fajar	Yogyakarta State University	Indonesia

Abstract No.	Poster No.	Abstract Title	Presenter Name	Affiliation	Country
A-0064	PE1-40	Harnessing computer-aided drug discovery for the development of potent allosteric inhibitors targeting EGFR in NSCLC	Mdaliasif Noor	Chonbuk National University Hospital	Korea
A-0120	PE1-42	The association between prevalence of tobacco use, nitrous oxide emissions and current health expenditure toward lung cancer in asian countries	Devi Yulia Rahmi	Universitas Andalas	Indonesia
A-0139	PE1-43	Self efficacy and quality of life in lung cancer patients: Systematic reviews	Mega Dwi Septivani	Padang State Polytechnic	Indonesia
A-0166	PE1-44	Revealed intermittent fasting benefit: How does the systematic review suggest lung cancer patients should undergo the most effective fasting?	Yesika Simbolon	Atmajaya University	Indonesia

Abstract No.	Poster No.	Abstract Title	Presenter Name	Affiliation	Country
A-0149	PE2-01	Comparison of overall survival between invasive mucinous and non-mucinous lung adenocarcinoma depending on stage and treatment modalities	Youjin Oh	John H. Stroger, Jr. Hospital of Cook County Health	USA
A-0104	PE2-02	Prognostic impact of mucinous vs. non-mucinous lung adenocarcinoma with lepidic growth pattern: a real-world analysis 22,914 patients from SEER	Yujung Heo	Feinberg School of Medicine, Northwestern University	Korea
A-0134	PE2-03	Integrative proteomic and phosphoproteomic: A pilot study on profiling Filipino non-small cell lung cancer patients	Aubrey Mae Lipa	University of the Philippines - Diliman	Philippines
A-0079	PE2-04	Potential and correlation of PET imaging and immune biomarkers for neoadjuvant immunotherapy in stage II/III non-small cell lung cancer	Eun Seong Lee	Korea University Guro Hospital	Korea
A-0066	PE2-05	Discovering potential biomarkers for diagnosis and prognosis of LUAD NSCLC	Baby Rorielyn Dimayacyac-Esleta	University of the Philippines-Diliman	Philippines
A-0061	PE2-06	Whole blood metabolomic patterns in non-small cell lung cancer: A comparative study with healthy controls	Kamal Baswal	Phd Student	India

Scientific Program